Aileens Pharma

The company was founded with the aim of providing the the first effective, safe and non-pharmacological treatment, for the main inflammatory skin diseases, in adults and children. LimpiAD is the first medical device of our pipeline based on HA-C40 a biotech mucopolysaccharide compound chemically conjugated to purified bacterial cell walls. Aileens owns patent on the bacterial strain and production method..
Aileens aims to have a disruptive and innovative therapeutic approach, seeing the recent scientific discoveries that shown the fundamental role played by the skin microbiome in the onset of inflammatory skin diseases.